Castle Biosciences (NASDAQ:CSTL) posted its quarterly earnings results on Monday. The company reported $0.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.33, Fidelity Earnings reports. The firm had revenue of $14.78 million during the quarter, compared to the consensus estimate of $10.28 million.
Shares of CSTL stock traded up $2.19 during mid-day trading on Tuesday, hitting $24.00. The company had a trading volume of 10,430 shares, compared to its average volume of 115,953. Castle Biosciences has a 52-week low of $15.26 and a 52-week high of $28.50. The company has a 50 day simple moving average of $19.66.
A number of equities analysts have weighed in on the stock. Canaccord Genuity upped their price target on shares of Castle Biosciences from $26.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Robert W. Baird upped their price target on shares of Castle Biosciences from $27.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 4th. BTIG Research upped their price target on shares of Castle Biosciences to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Svb Leerink assumed coverage on shares of Castle Biosciences in a research report on Monday, August 19th. They issued an “outperform” rating and a $28.00 price target for the company. Finally, Leerink Swann set a $33.00 price target on shares of Castle Biosciences and gave the stock a “buy” rating in a research report on Wednesday, September 4th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $31.60.
About Castle Biosciences
Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.
Featured Article: Why is insider trading harmful?
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.